The Efficacy and Safety of Pyramax in Mild to Moderate COVID-19 Patients

PHASE2CompletedINTERVENTIONAL
Enrollment

113

Participants

Timeline

Start Date

July 9, 2020

Primary Completion Date

March 25, 2021

Study Completion Date

April 15, 2021

Conditions
COVID-19
Interventions
DRUG

Pyronaridine-Artesunate

Pyramax

DRUG

Placebo

Placebo

Trial Locations (13)

Unknown

Korea University Ansan Hospital, Ansan

Chungnam national University Hospital, Daejeon

Inha University Hospital, Incheon

Gangnam Severance Hospital, Seoul

Hallym University Kangnam Sacred Heart Hospital, Seoul

Korea University Guro Hospital, Seoul

Kyungpook National University Hospital, Seoul

National Medical Center, Seoul

Sahmyook Medical Center, Seoul

Seoul Medical Center, Seoul

Severance Hospital, Seoul

The Catholic University of Korea, Eunpyeong St. Marys' Hospital, Seoul

Ajou University Hospital, Suwon

All Listed Sponsors
lead

Shin Poong Pharmaceutical Co. Ltd.

INDUSTRY

NCT04475107 - The Efficacy and Safety of Pyramax in Mild to Moderate COVID-19 Patients | Biotech Hunter | Biotech Hunter